Trump New Executive Orders Could Impact Indian Pharma Exports
News: President Donald Trump’s recent executive orders prioritize domestic pharmaceutical manufacturing in the U.S., posing major challenges for Indian drug exporters, especially in the generics market, according to a Nuvama Research report.
The move aims to re-shore production of APIs, KSMs, and raw materials, potentially disrupting global drug supply chains and reducing India’s cost advantage.
The orders also propose faster U.S. regulatory clearances, stricter compliance for foreign facilities, and higher fees for overseas manufacturers.
A possible requirement to disclose API origins could expose India’s reliance on Chinese imports, adding to scrutiny.
These measures reflect a broader focus on U.S. biosecurity and may significantly restructure the U.S. generics supply chain if fully implemented.
Source: The Economic Times
Join The Community
Recent News
-
India-Bangladesh Border Trade Hit Hard as DGFT Suspends Operations at Major Landports -
GMR Hyderabad International Airport to Acquire Full Stake in ESR GMR Logistics Park for ₹41 Crore -
India Seeks Interim Trade Deal with U.S. Ahead of July Tariff Implementation -
Blackstone to Invest ₹5127 Crore in Maharashtra to Develop 10 New Logistics and Industrial Parks -
Trump New Executive Orders Could Impact Indian Pharma Exports, Alter Global Drug Supply Chains: Report
2 Comments